These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33931299)

  • 1. [Radiotherapy for patients with early-stage glottic squamous cell carcinoma of the larynx: Interest of hypofractionation?].
    Tonneau M; Matta R; Lals S; Mirabel X; Crop F; Lacornerie T; Pasquier D; Escande A; Liem X
    Cancer Radiother; 2021 Dec; 25(8):801-810. PubMed ID: 33931299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 Fractional Dose-Escalation Study of Equipotent Stereotactic Radiation Therapy Regimens for Early-Stage Glottic Larynx Cancer.
    Sher DJ; Timmerman RD; Nedzi L; Ding C; Pham NL; Zhao B; Sumer BD
    Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):110-118. PubMed ID: 30880269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Closure of a Phase 1 Clinical Trial for SABR in Early-Stage Glottic Cancer.
    Kang BH; Yu T; Kim JH; Park JM; Kim JI; Chung EJ; Kwon SK; Kim JH; Wu HG
    Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):104-109. PubMed ID: 30880271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypofractionation vs. conventional radiotherapy fractionation in the conservative treatment of T1 glottic cancer: a prospective cohort study.
    Salas-Salas BG; Domínguez-Nuez DJ; Cabrera R; Ferrera-Alayón L; Lloret M; Lara PC
    Clin Transl Oncol; 2020 Jan; 22(1):151-157. PubMed ID: 31152306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phantom-to-clinic development of hypofractionated stereotactic body radiotherapy for early-stage glottic laryngeal cancer.
    Ding C; Chun SG; Sumer BD; Nedzi LA; Abdulrahman RE; Yordy JS; Lee P; Hrycushko B; Solberg TD; Ahn C; Timmerman RD; Schwartz DL
    Med Dosim; 2017 Summer; 42(2):90-96. PubMed ID: 28438431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective randomized trial comparing hypofractionation with conventional fractionation radiotherapy for T1-2 glottic squamous cell carcinomas: results of a Korean Radiation Oncology Group (KROG-0201) study.
    Moon SH; Cho KH; Chung EJ; Lee CG; Lee KC; Chai GY; Kang KM; Lee JY; Chung WK; Park WY; Kim JH
    Radiother Oncol; 2014 Jan; 110(1):98-103. PubMed ID: 24161568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncological outcome of vocal cord-only radiotherapy for cT1-T2 glottic laryngeal squamous cell carcinoma.
    de Ridder M; Rijken JA; Smits HJG; Smid EJ; Doornaert PAH; de Bree R
    Eur Arch Otorhinolaryngol; 2023 Jul; 280(7):3345-3352. PubMed ID: 36881167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study design and early result of a phase I study of SABR for early-stage glottic cancer.
    Yu T; Wee CW; Choi N; Wu HG; Kang HC; Park JM; Kim JI; Kim JH; Kwon TK; Chung EJ
    Laryngoscope; 2018 Nov; 128(11):2560-2565. PubMed ID: 29756264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypofractionated radiotherapy and surgery compared to standard radiotherapy in early glottic cancer.
    Kim KN; Dyer MA; Qureshi MM; Shah NK; Grillone GA; Faden DL; Jalisi SM; Truong MT
    Am J Otolaryngol; 2020; 41(5):102544. PubMed ID: 32505989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early-stage vocal cord cancer treated with hypofractionated radiotherapy to the larynx with or without concurrent chemotherapy.
    de Leo AN; Dagan R; Morris CG; Holtzman AL; Hitchcock KE; Bryant CM; Amdur RJ; Mendenhall WM
    Head Neck; 2022 Nov; 44(11):2513-2521. PubMed ID: 35950338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conventional fractionation should not be the standard of care for T2 glottic cancer.
    Dixon LM; Douglas CM; Shaukat SI; Garcez K; Lee LW; Sykes AJ; Thomson D; Slevin NJ
    Radiat Oncol; 2017 Nov; 12(1):178. PubMed ID: 29137654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smoking-induced radiation laryngeal necrosis after definitive radiotherapy alone for T1a glottic squamous cell carcinoma: A case report.
    Takagawa Y; Izumi S; Aoki M; Umeda Y; Ochiai K; Kumada J; Nakaya M; Kadomatsu Y; Itagaki S; Kita M
    Cancer Rep (Hoboken); 2022 Jul; 5(7):e1530. PubMed ID: 34396712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moderate hypofractionation for early laryngeal cancer improves local control: a systematic review and meta-analysis.
    Benson R; Prashanth G; Mallick S
    Eur Arch Otorhinolaryngol; 2020 Nov; 277(11):3149-3154. PubMed ID: 32377855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unexpected radiation laryngeal necrosis after carbon ion therapy using conventional dose fractionation for laryngeal cancer.
    Demizu Y; Fujii O; Nagano F; Terashima K; Jin D; Mima M; Oda N; Takeuchi K; Takeda M; Ito K; Fuwa N; Okimoto T
    Jpn J Clin Oncol; 2015 Nov; 45(11):1076-81. PubMed ID: 26355161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter prospective phase II study of postoperative hypofractionated stereotactic body radiotherapy (SBRT) in the treatment of early-stage oropharyngeal and oral cavity cancers with high risk margins: the STEREO POSTOP GORTEC 2017-03 trial.
    Biau J; Thivat E; Millardet C; Saroul N; Pham-Dang N; Molnar I; Pereira B; Durando X; Bourhis J; Lapeyre M
    BMC Cancer; 2020 Aug; 20(1):730. PubMed ID: 32758188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal.
    Huang SH; O'Sullivan B; Su J; Ringash J; Bratman SV; Kim J; Hosni A; Bayley A; Cho J; Giuliani M; Hope A; Spreafico A; Hansen AR; Siu LL; Gilbert R; Irish JC; Goldstein D; de Almeida J; Tong L; Xu W; Waldron J
    Cancer; 2020 Aug; 126(15):3426-3437. PubMed ID: 32478895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study Protocol: Prospective Study of Concurrent Chemoradiotherapy with S-1 and Hypofractionated Radiotherapy for Outpatients with Early Glottic Squamous Cell Carcinomas.
    Kimura K; Itoh Y; Okada T; Kubota S; Kawamura M; Nakahara R; Oie Y; Kozai Y; Takase Y; Tsuzuki H; Nishio N; Hiramatsu M; Fujimoto Y; Mizutani T; Hirakawa A; Naganawa S
    Asian Pac J Cancer Prev; 2018 May; 19(5):1195-1199. PubMed ID: 29801401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Early stages of laryngeal cancer (I-II stage) and therapeutic options: case report and review of literature].
    Margarino G; Schenone G; Scala M; Mereu P; Comandini D; Corvo R; Scolaro T; Badellino F
    Acta Otorhinolaryngol Ital; 1996 Feb; 16(1):40-6. PubMed ID: 8984839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benchmarking techniques for stereotactic body radiotherapy for early-stage glottic laryngeal cancer: LINAC-based non-coplanar VMAT vs. Cyberknife planning.
    Zhang Y; Chiu T; Dubas J; Tian Z; Lee P; Gu X; Yan Y; Sher D; Timmerman R; Zhao B
    Radiat Oncol; 2019 Nov; 14(1):193. PubMed ID: 31684993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypofractionated stereotactic radiotherapy for challenging brain metastases using 36 Gy in six fractions.
    Dumont Lecomte D; Lequesne J; Geffrelot J; Lesueur P; Barraux V; Loiseau C; Lacroix J; Leconte A; Émery É; Thariat J; Stefan D
    Cancer Radiother; 2019 Dec; 23(8):860-866. PubMed ID: 31677901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.